Europe Epilepsy Market Forecast to 2030 - Regional Analysis - by Type, Route of Administration, Treatment Type, Age Group, and Distribution Channel

List of Tables

The Europe epilepsy market was valued at US$ 1,940.58 million in 2022 and is expected to reach US$ 2,626.05 million by 2030; it is estimated to register a CAGR of 3.9% from 2022 to 2030.

Increasing Investments in Development of Epilepsy Therapies Drive Europe Epilepsy Market

The healthcare sector is transforming with rapid technological developments and innovation, enhancing healthcare services and quality of care. The epilepsy market is characterized by the presence of several small and large companies and organizations implementing various growth strategies. The availability of funding enables companies and organizations to boost production levels, expand into new markets, invest in new/improved technologies, and allocate more resources to R&D. A few of the notable investments in the epilepsy market, contributing to the market progress, have been mentioned below.

In March 2023, the Swedish government decided to commission Vinnova, Sweden's innovation agency, a total of US$ 7.7 million (80 million SEK) to establish a national innovation cluster for commercialization, skills development, and production capacity build-up for cell therapies and other advanced treatments such as gene therapy.

In November 2022, Scientists at Aston University in the UK, working on a project to develop new drug treatments to prevent the beginning of childhood epilepsy, were awarded US$ 2.4 million (£2 million) to discover the disease mechanism in the brain and the ways of epilepsy prevention. This three-year project funded by the Medical Research Council is a collaboration led by researchers in the College of Health and Life Sciences at Aston University, combined with Bristol University and Jazz Pharmaceuticals.

In July 2022, Cerebral Therapeutics secured US$ 40 million in the Series C round funding to get its implanted infusion epilepsy treatment ready for phase 3 development. The funding round was led by Lynx1 Capital Management among other investors, including RA Capital Management and Perceptive Advisors. Cerebral Therapeutics intends to deliver the specified levels of valproate to the central nervous system without causing weight gain, which was witnessed in subjects of oral formulation studies.

In November 2021, Neurava, a startup located in Indiana, received over US$ 0.65 million in seed funding led by Elevate Ventures with participation from Purdue Foundry, UCB Biopharma, First Leaf Capital, iO Life Ventures, and angel investors. The company is working on the development of a wearable device to monitor and alert users about the approaching risk of sudden, unexpected death caused by epilepsy.

In June 2021, Neurona Therapeutics Inc., a biotherapeutics company, successfully completed a US$ 41.5 million financing to advance the company's pipeline of wholly owned, off-the-shelf cell therapies for various indications, including NRTX-1001 (a Phase 1/2a clinical study), an inhibitory neuronal cell therapy for the treatment of chronic focal epilepsy.

Therefore, increasing investments in the development of advanced treatments propels the growth of the epilepsy market.

Europe Epilepsy Market Overview

The European epilepsy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the epilepsy market. The European epilepsy market is expected to witness significant growth during the forecast period due to factors such as the significant growth in elderly population, approvals of new drugs by regulatory authorities, increase in funding by governments to improve and develop effective drugs and treatments for seizures in the region.

Europe Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

Europe Epilepsy Market Segmentation

The Europe epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.

Based on type, the Europe epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.

In terms of route of administration, the Europe epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.

By treatment type, the Europe epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.

Based on age group, the Europe epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.

In terms of distribution channel, the Europe epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

By country, the Europe epilepsy market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. The UK dominated the Europe epilepsy market share in 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the Europe epilepsy market.

Product Code: BMIRE00030744

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Pipeline Studies for Epilepsy Therapy Approaches

4.1 Pipeline Studies for Epilepsy Therapy Approaches
- 4.1.1 Cell and Gene Therapy Approaches
- 4.1.2 Encapsulated cell bio delivery (ECB) system
- 4.1.3 Gene Therapy for Epilepsy Clinical Overview
  - 4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
    - 4.1.3.1.1 Gene Supplementation - Overview
    - 4.1.3.1.2 Gene Modulation - Overview
    - 4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
    - 4.1.3.1.4 Neuropeptides - Overview
    - 4.1.3.1.5 Engineered Channels - Overview
    - 4.1.3.1.6 Endogenous Channels - Overview
  - 4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
  - 4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
    - 4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
    - 4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
  - 4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
  - 4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
  - 4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
  - 4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. Europe Epilepsy Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Prevalence of Epilepsy
- 5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
- 5.2.1 Recall of Products
5.3 Market Opportunities
- 5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
- 5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - Europe Analysis

6.1 Europe: Epilepsy Market

7. Europe Epilepsy Market Analysis - by Type

7.1 Overview
7.2 Progressive Myoclonic Epilepsy
- 7.2.1 Overview
- 7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
- 7.3.1 Overview
- 7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
- 7.4.1 Overview
- 7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
- 7.5.1 Overview
- 7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Epilepsy Market Analysis - by Route of Administration

8.1 Overview
8.2 Oral
- 8.2.1 Overview
- 8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
- 8.3.1 Overview
- 8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Epilepsy Market Analysis - by Treatment Type

9.1 Overview
9.2 First Generation Drugs
- 9.2.1 Overview
- 9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
- 9.3.1 Overview
- 9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
- 9.4.1 Overview
- 9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Epilepsy Market Analysis - by Age Group

10.1 Overview
10.2 Adult
- 10.2.1 Overview
- 10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
- 10.3.1 Overview
- 10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Epilepsy Market Analysis - by Distribution Channel

11.1 Overview
11.2 Hospital Pharmacies
- 11.2.1 Overview
- 11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
- 11.3.1 Overview
- 11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
- 11.4.1 Overview
- 11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. Europe Epilepsy Market - Country Analysis

12.1 Europe: Epilepsy Market Overview
- 12.1.1 Europe: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
  - 12.1.1.1 United Kingdom: Epilepsy Market Overview
  - 12.1.1.2 United Kingdom: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.2.1 United Kingdom: Epilepsy Market Breakdown, by Type
    - 12.1.1.2.2 United Kingdom: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.2.3 United Kingdom: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.2.4 United Kingdom: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.2.5 United Kingdom: Epilepsy Market Breakdown, by Distribution Channel
  - 12.1.1.3 Germany: Epilepsy Market Overview
  - 12.1.1.4 Germany: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.4.1 Germany: Epilepsy Market Breakdown, by Type
    - 12.1.1.4.2 Germany: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.4.3 Germany: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.4.4 Germany: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.4.5 Germany: Epilepsy Market Breakdown, by Distribution Channel
  - 12.1.1.5 France: Epilepsy Market Overview
  - 12.1.1.6 France: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.6.1 France: Epilepsy Market Breakdown, by Type
    - 12.1.1.6.2 France: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.6.3 France: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.6.4 France: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.6.5 France: Epilepsy Market Breakdown, by Distribution Channel
  - 12.1.1.7 Spain: Epilepsy Market Overview
  - 12.1.1.8 Spain: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.8.1 Spain: Epilepsy Market Breakdown, by Type
    - 12.1.1.8.2 Spain: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.8.3 Spain: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.8.4 Spain: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.8.5 Spain: Epilepsy Market Breakdown, by Distribution Channel
  - 12.1.1.9 Italy: Epilepsy Market Overview
  - 12.1.1.10 Italy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.10.1 Italy: Epilepsy Market Breakdown, by Type
    - 12.1.1.10.2 Italy: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.10.3 Italy: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.10.4 Italy: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.10.5 Italy: Epilepsy Market Breakdown, by Distribution Channel
  - 12.1.1.11 Rest of Europe: Epilepsy Market Overview
  - 12.1.1.12 Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.12.1 Rest of Europe: Epilepsy Market Breakdown, by Type
    - 12.1.1.12.2 Rest of Europe: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.12.3 Rest of Europe: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.12.4 Rest of Europe: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.12.5 Rest of Europe: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
- 13.3.1 Overview
13.4 Inorganic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 Abbott Laboratories
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Pfizer Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Eisai Co Ltd
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 UCB SA
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 CombiGene AB
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 LivaNova Plc
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Novartis AG
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Medtronic Plc
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 GSK Plc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 H. Lundbeck AS
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners